2J. van Ryn,M. Pairet.Clinical experience with cyclooxygenase-2 inhibitors[J]. Inflammation Research . 1999 (5)
3M erck W ithdraws V ioxx.FDA Issues Pub lic Health Advisory. www.fda.com . 2004
4FDA Statem ent on the Halting of a C lin ical Trial of the Cox-2 In-h ib itor Celebrex. www.fda.gov . 2004
5Topoi EJ.Failing the Pub lic Health—Rofecoxib. M erck and theFDA NEJM . 2004
6Keane WF.M erck Announces Voluntary W orldw ide W ithdrfdwalofV ioxx. wwww.m erck.com . 2004
7Vane JR.Inh ib ition of prostagland in synthesis as a m echan ism ofaction for asp irin-like drugs. Nature . 1971
8L ipsky LP,Abram son SB,C rofford L,et al.The classification ofcyclooxygenase inh ib itors. The Journal of Rheumatology . 1998
9Langman M J,Jensen DM,W atson D J,et al.Lower incidence ofclin ically evident upper-G I perforations,u lcers and b leeds in pa-tients treated w ith rofecoxib vsnonspecific cyclooxygenase inh ib i-tors. Gastroenterology . 1999
10Sheng HG,Shao JY,K irkland SC,et al.Inh ib ition of human co-lon cancer cell growth by selective inh ib ition of cyclooxygenase-2. The Journal of Clinical Investigation . 1997
